TABLE 1

Clinical Results of PRRT in Gastroenteropancreatic NETs

TherapyStudyNo. of patientsCRPRScheduleProgression at baselineResponse criteriaOutcome
90Y-octrotideWaldherr, 2002 (9)364%20%7.4 GBq/m2 in 4 cycles100%WHONot assessed
Bodei, 2003 (10)210%28%2.96–5.55 GBq/cycle × 2NAWHOTTP, 10 mo
Valkema, 2006 (11)580%9%0.93–2.78 GB/m2/cycle81%SWOGTTP, 29 mo
Bushnell, 2010 (12)900%4%4.4 GBq/cycle × 3100%SWOGPFS, 16 mo
Imhof, 2011 (14)8210.2%38%1–10 cycles (median, 2), various activitiesNARECISTNA (mean OS, 4–60 mo)
177Lu-octreotateKwekkeboom, 2008 (4)3102%28%27.8–29.6 GBq in 3–4 cycles43%SWOGPFS, 33 mo
Bodei, 2011 (13)393%31%3.7–29.2 GBq in 4–6 cycles of 3.7–7.4 GBq76%RECISTTTP, 36 mo
  • CR = complete response; NA = not applicable; PFS = progression-free survival; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SWOG = Southwest Oncology Group; TTP = time to progression; WHO = World Health Organization.